0000950170-23-013722.txt : 20230420 0000950170-23-013722.hdr.sgml : 20230420 20230420181719 ACCESSION NUMBER: 0000950170-23-013722 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230418 FILED AS OF DATE: 20230420 DATE AS OF CHANGE: 20230420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Miller Andrew Craig CENTRAL INDEX KEY: 0001777760 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 23834136 MAIL ADDRESS: STREET 1: C/O KARUNA THERAPEUTICS, INC. STREET 2: 33 ARCH STREET, SUITE 3110 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0407 4 2023-04-18 0001771917 Karuna Therapeutics, Inc. KRTX 0001777760 Miller Andrew Craig C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, 26TH FLOOR BOSTON MA 02110 false true false false Chief Operating Officer true Common Stock 2023-04-18 4 M false 30000 9.20 A 60900 D Common Stock 2023-04-18 4 S false 30000 200.16 D 30900 D Common Stock 2023-04-20 4 M false 8500 9.20 A 39400 D Common Stock 2023-04-20 4 S false 15000 200.13 D 24400 D Option (right to buy) 9.20 2023-04-18 4 M false 30000 0 D 2029-03-20 Common Stock 30000 240492 D Option (right to buy) 9.20 2023-04-20 4 M false 8500 0 D 2029-03-20 Common Stock 8500 231992 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019. /s/ Troy Ignelzi, Attorney-in-Fact 2023-04-20